Status:
COMPLETED
Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)
Lead Sponsor:
Celgene
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18-55 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine whether ozanimod is effective in the treatment of relapsing multiple sclerosis (RMS).
Eligibility Criteria
Inclusion
- Multiple sclerosis as diagnosed by the revised 2010 McDonald criteria
- EDSS score between 0 and 5.0 at baseline
Exclusion
- • Primary progressive multiple sclerosis
Key Trial Info
Start Date :
December 3 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 22 2016
Estimated Enrollment :
1346 Patients enrolled
Trial Details
Trial ID
NCT02294058
Start Date
December 3 2014
End Date
December 22 2016
Last Update
November 25 2020
Active Locations (224)
Enter a location and click search to find clinical trials sorted by distance.
1
Xenosciences Inc
Phoenix, Arizona, United States, 85004
2
St Josephs Hospital and Medical Center
Phoenix, Arizona, United States, 85013
3
Northwest Neuro Specialists PLLC
Tucson, Arizona, United States, 85712
4
Alta Bates Summit Medical Center
Berkeley, California, United States, 94705